Abstract
A clinical trial of nivolumab in 10 patients with pediatric cancer with high tumor mutational burden demonstrated complete responses in 50% of patients. This result recapitulates multiple clinical trial results in high mutation–burden adult cancers and may redefine best practice in the setting of germline DNA mismatch repair–based susceptibility.
This content is only available via PDF.
©2023 The Authors; Published by the American Association for Cancer Research
2023
American Association for Cancer Research
This open access article is distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) license.
